Palatin Technologies Inc. (PTN)
-NYSE MKT 0.64 0.00(0.00%) 10:41AM EDT
| Prev Close: | 0.64 |
|---|
| Open: | 0.66 |
|---|
| Bid: | 0.64 x 1000 |
|---|
| Ask: | 0.64 x 1600 |
|---|
| 1y Target Est: | 4.25 |
|---|
| Beta: | 1.57 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.64 - 0.66 |
|---|
| 52wk Range: | 0.40 - 1.20 |
|---|
| Volume: | 21,948 |
|---|
| Avg Vol (3m): | 157,530 |
|---|
| Market Cap: | 24.93M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.27 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- PALATIN TECHNOLOGIES INC FinancialsEDGAR Online Financials(Fri, May 17)
- Palatin's CEO Discusses F3Q2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 14)
- Palatin Technologies Earnings Call scheduled for 11:00 am ET todayCCBN(Tue, May 14)
- Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual DysfunctionPR Newswire(Tue, May 14)
- Q3 2013 Palatin Technologies Earnings Release - Before Market OpenCCBN(Tue, May 14)
- PALATIN TECHNOLOGIES INC Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Tue, May 14)
- PALATIN TECHNOLOGIES INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, May 13)
- Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013PR Newswire(Wed, May 8)
- Huge Potential But Tough Entry For Female Sexual Dysfunction Drugsat Seeking Alpha(Tue, May 7)
- Palatin Tech announces notification of patent allowance for '238 applicationat theflyonthewall.com(Thu, May 2)
- Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual DysfunctionPR Newswire(Thu, May 2)
- These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potentialat Seeking Alpha(Wed, Apr 24)
- Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific PeptidesPR Newswire(Tue, Mar 19)
- Palatin Technologies To Present At The 25th Annual ROTH ConferencePR Newswire(Fri, Mar 15)
- Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care ConferencePR Newswire(Mon, Mar 4)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 1,165.21 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | -0.22 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.04 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Palatin Technologies, Inc., a biopharmaceutical company, engages in the development of peptide therapeutics for the treatment of diseases. Its drug development programs include Bremelanotide, a peptide melanocortin receptor agonist that is in Phas...
View More 
0.41%